



F-star Awarded “Life Science Innovation” Company of the Year by Business Weekly

Cambridge, UK – 24 March 2017 – F-star, a biopharmaceutical company developing novel bispecific antibodies with a focus on immuno-oncology, today announced it has been awarded “[Life Science Innovation](#)” Company of 2017 by Business Weekly, in recognition of its work to further the cause of life science discovery for the benefit of human healthcare.

“We are delighted to receive this “Life Science Innovation” award as a significant peer-recognition of the clinical potential of our proprietary Modular Antibody Technology™ and the assets that we are progressing towards patients” said John Haurum, CEO of F-star. “We are grateful to Business Weekly, AstraZeneca/MedImmune, sponsor of the award and the judging panel who selected us amongst many world-class biotechs in the Cambridge cluster.”

F-star is focused on developing treatments to improve cancer therapy. The company is pursuing an immuno-oncology approach through the discovery and development of bispecific antibodies that can transform cancer treatment by harnessing the body’s natural immune response and simultaneously targeting tumours in multiple ways.

F-star was also a one of the three finalist in the ‘[Employer of the Year](#)’ category for the Cambridge News Excellence Awards 2017.



Pure Award for
Employer of the Year
FINALIST

-Ends-

For further information, please contact:

F-star

Pierre Peotta

Communications Manager

+44 (0)1223 804 322

+44 (0)7392 080 279

pierre.peotta@f-star.com

media@f-star.com

Instinctif Partners

Sue Charles/Daniel Gooch

+44 (0)20 7866 7905

F-star@instinctif.com

About F-star

F-star is a clinical-stage biopharmaceutical company developing bispecific antibody immuno-oncology products selected for their potential to transform the treatment of cancer. Through the application of its highly efficient Modular Antibody Technology™ platform, F-star is the only biotechnology company able to rapidly create bispecific antibodies with properties virtually identical to a typical antibody. This offers unprecedented ease in the discovery, development, and manufacturing of bispecific antibody products. F-star has currently one programme in the clinic with a second immuno-oncology programme heading toward IND. The Company has built a comprehensive IP estate around its technology and product pipeline, with over 50 patent applications filed and over 25 granted patents.

F-star's management team has a well-established track record in building successful biotech companies, and developing biologics. The team is advised by a world-leading scientific advisory board and a highly experienced board of directors. The strength of the technology and programmes has been leveraged through partnerships with leading biopharmaceutical companies including AbbVie, Bristol-Myers Squibb, Merck KgaA and Denali Therapeutics. F-star has raised close to \$100M in non-dilutive capital and revenues. The company currently employs over 80 people at its research site in Cambridge, UK.

For more information visit www.f-star.com